LEVODOPA/CARBIDOPA GxP 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

البلد: أستراليا

اللغة: الإنجليزية

المصدر: Department of Health (Therapeutic Goods Administration)

العنصر النشط:

levodopa, Quantity: 250 mg; carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg)

متاح من:

Arrotex Pharmaceuticals Pty Ltd

الشكل الصيدلاني:

Tablet, uncoated

تركيب:

Excipient Ingredients: crospovidone; magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch

طريقة التعاطي:

Oral

الوحدات في الحزمة:

10 tablets, 20 tablets, 100 tablets

نوع الوصفة الطبية :

(S4) Prescription Only Medicine

الخصائص العلاجية:

LEVODOPA/CARBIDOPA GxP is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GxP frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.

ملخص المنتج:

Visual Identification: Round, light blue uncoated tablets with 'C' on one side and '20' on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

الوضع إذن:

Registered

تاريخ الترخيص:

2018-01-11